We are live on ! Find out more

MOBI

Mobia Medical

MOBI

Market cap $283M

8.51 USD

-0.29

3.3%

At close Updated Oct 7, 4:00 PM EDT

1 day

-3.3%

5 days

-9.28%

1 month

-23.26%

3 months

-31.09%

6 months

-27.57%

Year to date

-27.57%

1 year

-27.57%

5 years

-27.57%

10 years

-27.57%

About: Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines

AUSTIN, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 Guideline for Adult Stroke Rehabilitation and Recovery: A Guideline From the American Heart Association (AHA) and American Stroke Association (ASA), published August 27, 2026 in Stroke as a treatment option to improve upper-limb function and impairment for chronic stroke survivors.

Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines

Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript

Mobia Medical Q2 Earnings Call Highlights

Mobia Medical NASDAQ: MOBI reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded across new and existing stroke-care programs.

Mobia Medical Q2 Earnings Call Highlights

Mobia Medical Reports Second Quarter 2026 Financial Results

AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Highlights Reported revenue of $13.5 million, representing 102% growth over the prior year period Achieved gross margin of 83.2% Announced publication of two-year VNS-REHAB follow up data in Neurology®, demonstrating durable and clinically meaningful improvement in upper-limb motor function, activities of daily living, and quality of life Completed initial public offering, raising approximately $134.0 million in net proceeds Appointed Myriam Curet, M.D.

Mobia Medical Reports Second Quarter 2026 Financial Results

Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors

AUSTIN, Texas, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Myriam Curet, M.D., to the Board as an independent director, effective July 30, 2026.

Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors

Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026

AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report second quarter 2026 financial results on Tuesday, August 11, 2026. Mobia Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026

Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.

Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule

AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Centers for Medicare and Medicaid Services (CMS) has proposed to maintain CPT® Code 64568, the procedure code used for the Vivistim® procedure, under the New Technology Ambulatory Payment Classification (APC) 1580 for calendar year (CY) 2027, with an associated hospital outpatient payment rate of approximately $45,000, unchanged from the CY 2026 rate. CMS is expected to publish the final Hospital Outpatient Prospective Payment System (OPPS) rule in November of this year, with any changes taking effect January 1, 2027.

Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule

Primary Markets Group May 2026 U.S. IPO Monthly

The U.S. IPO market maintained its strong momentum in May with 12 offerings raising $13.1 billion in total proceeds, which was well above April's $8.2 billion in total proceeds but one short on deal count. The largest deal of the month was technology firm Cerebras Systems' $6.4 billion raise, making it the largest IPO since Medline Inc.'s $7.2 billion raise in December 2025 and the biggest tech IPO since Uber Technologies' $8.1 billion in May 2019. The healthcare sector saw three new issuers, led by GMR Solutions' $478.7 million offering.

Primary Markets Group May 2026 U.S. IPO Monthly

See News Rankings

Price charts implemented using Lightweight Charts™